Gotemba Press Release

Title Picture
06/05/2018 - 11:20
Chugais HEMLIBRA Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors
Chugai's picture
Chugai
05/20/2018 - 22:22
Chugai Presents Results of Two Pivotal Phase III Studies
Chugai's picture
Chugai
05/15/2018 - 23:31
Chugais ALK Inhibitor Alecensa Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan
Chugai's picture
Chugai
01/31/2018 - 20:59
Further Improving Access to Therapies for Non-Small Cell Lung Cancer
Chugai's picture
Chugai
12/20/2017 - 23:29
EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
Chugai's picture
Chugai
12/07/2017 - 03:45
Chugais Emicizumab Every Four Weeks Showed Positive Interim Results
Chugai's picture
Chugai
11/29/2017 - 03:33
TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for gMSC
Chugai's picture
Chugai
11/20/2017 - 00:45
Meets Primary Endpoint in Phase III Study
Chugai's picture
Chugai
11/08/2017 - 05:55
Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
Chugai's picture
Chugai
10/04/2017 - 21:23
Results of Preclinical Study Published in Science Translational Medicine
Chugai's picture
Chugai
08/24/2017 - 00:52
Chugais Emicizumab Receives Priority Review Designation by FDA
Chugai's picture
Chugai
06/26/2017 - 02:35
Chugais Bispecific Antibody Emicizumab to Present
Chugai's picture
Chugai
06/07/2017 - 01:51
Marketing and Manufacturing Right Transfer of 13 Long-Term Listed Products
Chugai's picture
Chugai
06/06/2017 - 02:10
Data of Chugai's Alecensa Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
Chugai's picture
Chugai
05/11/2017 - 01:58
Results of the J-ALEX Study for Chugai's Alecensa are Published in The Lancet Online
Chugai's picture
Chugai
04/10/2017 - 03:11
Met Its Primary Endpoint in the ALEX Study
Chugai's picture
Chugai
04/04/2017 - 03:52
A First Approach in the Japanese Pharmaceutical Industry
Chugai's picture
Chugai
04/01/2017 - 02:25
Transfer of Rights to Insomnia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
Chugai's picture
Chugai
03/30/2017 - 02:57
Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund
Chugai's picture
Chugai
02/27/2017 - 03:45
Chugais ALK Inhibitor Alecensa
Chugai's picture
Chugai
02/21/2017 - 03:28
- Alecensa is Available Now in Japan, the United States and Europe -
Chugai's picture
Chugai
12/22/2016 - 04:10
PharmaMar and Chugai Pharmaceutical Enter into
Chugai's picture
Chugai
12/21/2016 - 23:42
Chugais Bispecific Antibody Emicizumab for Hemophilia A Meets Primary Endpoint in Phase lll Study
Chugai's picture
Chugai
10/04/2016 - 22:39
Chugais ACTEMRA /RoACTEMRA Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis
Chugai's picture
Chugai
10/04/2016 - 00:14
Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
Chugai's picture
Chugai
07/20/2016 - 23:57
Chugai and Galderma Announce Global License Agreement
Chugai's picture
Chugai
06/01/2016 - 06:10
Chugai Announces License Agreement for Recycling Antibody SA237
Chugai's picture
Chugai